RAP1B and neoplasm: As described above (Section 3.1.1), endothelial deletion of Rap1B leads to inflammatory derepression, enhancing CD45+ and CD8+ T-cell infiltration and activation in tumors, contributing to immune-mediated tumor regression—an effect reversed by CD8+ T-cell depletion [40].